SIGHT SCIENCES INC. - COMMON STOCK

Sight Sciences to Host SAHARA 6 Month RCT Results Reception at the American Academy of Ophthalmology 2023

19 10 2023 16:05:00 提供 Nasdaq GlobeNewswire

Sight Sciences Announces Presentation of Successful Phase I Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease at the American Academy of Optometry Annual Meeting

12 10 2023 16:05:00 提供 Nasdaq GlobeNewswire

Sight Sciences Announces New, Large-Scale MIGS Data from 41st Congress of ESCRS Demonstrating TCOR™ Using OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma

03 10 2023 08:30:00 提供 Nasdaq GlobeNewswire

Sight Sciences Provides Revenue Guidance for the Third Quarter of 2023 and Updates Revenue Guidance for Full Year 2023

11 9 2023 16:06:00 提供 Nasdaq GlobeNewswire

Sight Sciences Appoints Matt Link as Chief Commercial Officer

11 9 2023 16:05:00 提供 Nasdaq GlobeNewswire

Sight Sciences to Present at the Upcoming Morgan Stanley 21st Annual Global Healthcare Conference

30 8 2023 16:05:00 提供 Nasdaq GlobeNewswire

Sight Sciences Reports Second Quarter 2023 Financial Results and Reaffirms Guidance for Full Year 2023

03 8 2023 16:05:01 提供 Nasdaq GlobeNewswire

Sight Sciences to Report Second Quarter 2023 Financial Results on August 3, 2023

20 7 2023 16:05:00 提供 Nasdaq GlobeNewswire

Sight Sciences Announces Positive Results and Primary Endpoint Successfully Met in SAHARA, a Randomized Controlled Clinical Trial Comparing Interventional Eyelid Procedures Enabled by TearCare® Technology to Restasis¹ for the Treatment of Dry Eye

20 7 2023 08:30:00 提供 Nasdaq GlobeNewswire

Cigna Expands Coverage of Glaucoma Surgical Procedures to Include Canaloplasty and Goniotomy (Trabeculotomy)

21 6 2023 08:30:00 提供 Nasdaq GlobeNewswire

Sight Sciences Announces Addition of New Director Catherine Mazzacco

09 6 2023 16:05:00 提供 Nasdaq GlobeNewswire

Sight Sciences Two Year Multicenter Study Results Show Sustained Reductions in Both Intraocular Pressure (IOP) and Glaucoma Medication Use in Mild-Moderate Primary Open Angle Glaucoma Patients Treated with a Procedure Enabled with the OMNI® Surgical System Technology

23 5 2023 08:30:01 提供 Nasdaq GlobeNewswire

Sight Sciences Announces 12-month Results from the First Minimally Invasive Glaucoma Surgery (MIGS) Comparative Analysis of Real-World Data (RWD) from the American Academy of Ophthalmology IRIS® Registry

06 5 2023 11:30:00 提供 Nasdaq GlobeNewswire

Sight Sciences Reports First Quarter 2023 Financial Results and Reaffirms Guidance for Full Year 2023

04 5 2023 16:05:01 提供 Nasdaq GlobeNewswire

Sight Sciences' Glaucoma and Dry Eye Technologies to be Featured in Multiple Clinical Presentations at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

01 5 2023 16:05:00 提供 Nasdaq GlobeNewswire

Sight Sciences to Present at the Upcoming Bank of America Securities 2023 Health Care Conference

26 4 2023 16:05:01 提供 Nasdaq GlobeNewswire

Sight Sciences to Report First Quarter 2023 Financial Results on May 4, 2023

20 4 2023 16:05:00 提供 Nasdaq GlobeNewswire

Sight Sciences to Host Surgical Glaucoma Investor Symposium on Friday, May 5, 2023

13 4 2023 16:05:41 提供 Nasdaq GlobeNewswire

Sight Sciences Appoints Ali Bauerlein as Chief Financial Officer

03 4 2023 16:05:00 提供 Nasdaq GlobeNewswire

Sight Sciences Defeats Invalidity Challenges Filed By Alcon and Ivantis In The U.S. Patent Office

30 3 2023 08:00:00 提供 Nasdaq GlobeNewswire